Inspiremd Stock Price, News & Analysis

InspireMD announced its third-quarter 2022 results, showcasing a 38.8% year-over-year growth in CGuard™ revenue, reaching $1.43 million. The company sold 2,624 stents, up from 1,709 in 2021. Operating expenses increased 20.7% to $4.98 million, leading to a net loss of $4.53 million or $0.58 per share. A strategic partnership with NAMSA aims to enhance device development. The company continues to progress with its U.S. IDE trial, currently enrolling at 24 sites, and anticipates completion by end of Q1 2023.

InspireMD (Nasdaq: NSPR) will report its Q3 2022 financial results on November 8, 2022, before the markets open. A conference call and webcast will be held at 8:30 a.m. EDT to discuss the results and provide updates on corporate developments. Investors are encouraged to access the webcast 15 minutes prior. The company aims to set industry standards for carotid stenting through its proprietary MicroNet® technology, enhancing patient outcomes and preventing strokes.

InspireMD, Inc. (NASDAQ: NSPR) announced its participation in the 2022 Transcatheter Cardiovascular Therapeutics (TCT) Conference, scheduled from September 16-19, 2022, in Boston, MA. The presentation will focus on the CGuard™ Embolic Prevention System and its effectiveness in treating carotid stenosis-related cerebral injury.

Prof. Piotr Musialek will present on September 17, 2022, at 4:15 pm ET. The study aims to provide insights into the clinical application of their technology, which seeks to enhance outcomes in carotid stenting.

InspireMD, Inc. (NASDAQ: NSPR) has partnered with NAMSA for strategic outsourcing to enhance medical device development and commercialization. This collaboration aims to expedite the launch of InspireMD's CGuard™ Embolic Prevention System for carotid artery disease and stroke prevention. Both companies focus on accelerating clinical development through NAMSA's expertise in navigating regulatory requirements. InspireMD plans to leverage this partnership to advance its MicroNet™ technology, aiming to establish it as a standard in the carotid stenting market.

InspireMD reported a 47.8% growth in CGuard™ revenue year-over-year, achieving $1,505,000 in the second quarter of 2022. This surge in sales volume came from selling 2,602 stent systems compared to 1,623 in Q2 2021. Despite the positive revenue growth, the company's net loss widened to $4,636,000 or $0.59 per share, up from $3,507,000, as operating expenses increased significantly. Total revenue for the first half of 2022 reached $2,714,000, marking a 32.8% rise year-over-year.

InspireMD (Nasdaq: NSPR) will report its second quarter 2022 financial results on August 9, 2022, before market opening. The company, known for the CGuard™ Embolic Prevention Stent System, aims to provide significant clinical advancements in treating carotid artery disease. A conference call will occur at 8:30 a.m. EDT on the same day to discuss these results and corporate updates. InspireMD focuses on ensuring long-term stroke-free outcomes through its proprietary MicroNet® technology.

InspireMD, Inc. (Nasdaq: NSPR) appointed endovascular pioneer Dr. Juan Parodi as a strategic advisor on July 14, 2022. Known for performing the first endovascular repair procedure in 1990, Dr. Parodi brings significant expertise to InspireMD's efforts in stroke prevention. CEO Marvin Slosman emphasized Dr. Parodi's contributions to vascular surgery, particularly with the CGuard™ Embolic Prevention System, which aims to enhance patient outcomes in carotid artery disease. Dr. Parodi's involvement underscores InspireMD's commitment to innovation and clinical performance.

InspireMD (Nasdaq: NSPR) showcased its CGuard™ Embolic Prevention System at the LINC 2022 conference, emphasizing its advantages in carotid revascularization. A successful live procedure highlighted CGuard's optimal vessel conformability and MicroNet mesh technology, offering superior patient protection. Results from various studies presented at LINC demonstrated significantly lower rates of death, stroke, and myocardial infarction with CGuard compared to traditional stents, reinforcing its market leadership in stroke prevention.

InspireMD will showcase its CGuard™ Embolic Prevention System (EPS) at the upcoming LINC 2022 conference in Leipzig, Germany, from June 6-9. The live case transmission aims to exhibit the system's ease-of-use and patient safety features. CEO Marvin Slosman highlighted the significance of the event for engaging with the clinical community. Presentations will feature evidence supporting the superiority of CGuard™ EPS over conventional stents. The conference serves as a vital platform for discussing advancements in vascular medicine.